# Survodutide

Canonical source: https://retacompare.com/encyclopedia/survodutide

Dual GLP-1 / glucagon receptor agonist. Glucagon arm drives hepatic lipid mobilization and energy expenditure.

Reference facts

Also known asBI 456906CategoryGLP-1 & MetabolicMechanism of actionDual GLP-1 / glucagon receptor agonist. Glucagon arm drives hepatic lipid mobilization and energy expenditure.TargetsGLP-1R, GCGRIndications under research or approvedObesity, MASHRegulatory status (reference entry)Investigational (Phase 3 SYNCHRONIZE; FDA Breakthrough Therapy for MASH 2024)Half-life~5 daysSequenceHSQGTFTSDYSKYLDEKAAKEFIEWLLEGGPSSGAPPPSSequence notesDual GLP-1 / glucagon receptor agonist with C18 fatty acid moiety and Aib stabilization.Molecular weight (Da)4500Originator / sponsorBoehringer Ringer / Zealand PharmaFirst reported2022
    Primary References

Survodutide MASH Phase 2, NEJM 2024

SYNCHRONIZE-1 (NCT06066515)


    Explore research articles about Survodutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Survodutide MASH Phase 2, NEJM 2024: https://www.nejm.org/doi/full/10.1056/NEJMoa2401755
- SYNCHRONIZE-1 (NCT06066515): https://clinicaltrials.gov/study/NCT06065515